Giant Cell Arteritis

The PBS subsidises tocilizumab for patients with active giant cell arteritis.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with tocilizumab under the National Health Act 1953, section 85 for patients aged 50 years or older with active giant cell arteritis (GCA).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing tocilizumab.

Treatment specifics

To be eligible for PBS-subsidised treatment with tocilizumab, patients must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of active GCA.

A patient may only qualify for PBS-subsidised treatment with tocilizumab for active GCA once in a lifetime. The treatment mustn’t exceed 52 weeks in total including initial and continuing applications.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised tocilizumab to treat active GCA can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised tocilizumab to treat active GCA can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 51319